2026年10月16日星期五
M
寰宇通鑑
全球快訊
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Samsung remains top brand in Asia for third year: Nikkei Research poll

來源 日经 Nikkei Asia5 小時前
內容摘要

This item is a 英语-language original; headline and summary shown as published.

Samsung remains top brand in Asia for third year: Nikkei Research poll

本站僅提供標題與摘要索引，完整內容與版權均歸原發布方所有，請點擊原文連結閱讀。

前往原文
所屬頻道
財經
所屬地區
日本
原文語種
英语
條目編號
business-faee652e

Comments 0 comments

No comments yet. Be the first.

Samsung remains top brand in Asia for third year: Nikkei Research poll · 寰宇通鑑